Quantum Genomics SA
Quantum Genomics SA (ALQGC.PA) Company Profile & Overview
Explore Quantum Genomics SA’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Quantum Genomics SA (ALQGC.PA) Company Profile & Overview
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.